Latest Licensing News

Meteoric Resources NL has reported a significant update to its Caldeira Rare Earth Project, highlighting improved financial metrics and exceptional drilling results that reinforce its position as a low-cost rare earths producer.

Metal Bank Limited reports significant progress across its Australian and MENA projects, including a strategic review of its Livingstone Gold Project and new exploration rights in Saudi Arabia and Jordan, supported by a fully subscribed $1.56 million entitlement offer.

Power Minerals has made significant progress with its maiden diamond drilling program at the Niobio Project in Brazil, while deciding not to proceed with the Tântalo Project acquisition due to access issues. The company also settled outstanding debts with Ultra Lithium, positioning itself for focused growth in South America.

1414 Degrees Ltd reports strong progress in its hydrogen and thermal energy storage projects, securing full funding for commercialisation and advancing key customer agreements. The company is poised to scale its innovative technologies amid ongoing operational enhancements.

archTIS Limited reported a 12% increase in annual recurring revenue to $4 million and achieved net positive cash flow from operations, while signing a binding term sheet to acquire Direktiv’s assets, signaling strategic growth in data-centric security.

Native Mineral Resources has secured key Queensland gold assets and is advancing refurbishment of the Blackjack Processing Plant, targeting production restart by Q3 2025. The company’s recent capital raises underpin its ambitious development plans.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

TZ Limited reported a quarterly revenue shortfall in Q2 FY2025 due to delayed US projects but anticipates a strong rebound post-election and strategic growth through acquisition.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.